Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
NCT05930210 · View on ClinicalTrials.gov ↗
Study Summary
This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (\<16 cm2 vs ≥16 cm2 ) will be included as a stratification factor. Subjects will be randomized 1:1 to receive ENERGI-F703 GEL or vehicle control using an interactive web response system for randomization to automatically assign a unique subject randomization number. Total duration of the study will be up to 31 weeks including Screening visit (approximately 2 to 3 weeks), double-blind dosing/observation phase (16 weeks), and a safety follow-up of 12 weeks after the last administration of study treatment.
Conditions Studied
Interventions
- DRUG ENERGI-F703 GEL
- DRUG ENERGI-F703 matched vehicle
Study Locations (20)
Other
- Ditmanson Medical Foundation Chia-Yi Christian Hospital — Chiayi City
- Kaohsiung Medical University Hospital — Kaohsiung City
- China Medical University Hospital — Taichung
- Kung Tien General Hospital — Taichung
- Taichung Veterans General Hospital — Taichung
- Chi Mei Medical Center — Tainan
- National Cheng Kung University Hospital — Tainan
- Cathay General Hospital — Taipei
- MacKay Memorial Hospital — Taipei
- National Taiwan University Hospital — Taipei
Florida
- A and D Doctor Center — Miami
- Bioclinical Research — Miami
- Reliant Medical Research — Miami
- Advanced Medical Research Institute — Miami
- New Horizons Research — Palmetto Bay
Georgia
- IACT Health — Columbus
Tennessee
- The Jackson Clinic PA — Jackson
Texas
- Mt. Olympus Medical Research — Houston
Utah
- Wasatch Clinical Research — Salt Lake City
Virginia
- Salem Veterans Affairs Medical Center VAMC — Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05930210
The ClinicalTrials.gov registry entry for NCT05930210 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Energenesis Biomedical Co., which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions — of which ENERGI-F703 GEL is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05930210 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Other, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05930210 about?
NCT05930210 is a clinical study titled "A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer". This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (\<16 cm2 vs ≥16 cm2 ) wi...
What is the current status of trial NCT05930210?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2023-05-30. Estimated completion is 2026-03-31.
What conditions does trial NCT05930210 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Diabetic Foot Ulcer, Foot Ulcer, Wound. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05930210?
The interventions under investigation include: ENERGI-F703 GEL (DRUG), ENERGI-F703 matched vehicle (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05930210?
This trial is sponsored by Energenesis Biomedical Co., which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05930210 being conducted?
This trial has 20 study locations across Florida, Georgia, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.